KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Assets (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Non-Current Assets for 18 consecutive years, with $513.0 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets rose 30.2% year-over-year to $513.0 million; the TTM value through Mar 2026 reached $2.0 billion, up 30.66%, while the annual FY2025 figure was $533.2 million, 39.08% up from the prior year.
  • Non-Current Assets hit $513.0 million in Q1 2026 for Ionis Pharmaceuticals, down from $533.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $533.2 million in Q4 2025 and bottomed at $265.0 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $373.5 million, with a median of $354.4 million recorded in 2023.
  • Year-over-year, Non-Current Assets grew 1.65% in 2024 and then skyrocketed 39.99% in 2025.
  • Ionis Pharmaceuticals' Non-Current Assets stood at $331.2 million in 2022, then rose by 5.14% to $348.2 million in 2023, then rose by 10.1% to $383.4 million in 2024, then soared by 39.08% to $533.2 million in 2025, then dropped by 3.78% to $513.0 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $513.0 million, $533.2 million, and $514.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.